AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Teva, Ranbaxy co-launch hypertension medication.
(From Israel Business Arena)
Byline: Globes correspondent
Israel's Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA) and India's Ranbaxy Pharmaceuticals Inc. announced today that Teva has begun commercially shipping quinapril hydrochloride tablets, 5 mg, 10 mg, 20 mg and 40 mg.
Quinapril HCl tablets are the AB-rated generic equivalent of Accupril tablets, made by Parke Davis (a division of Pfizer), for the treatment of high blood pressure.
The tablets are manufactured under Ranbaxy's ANDA, which received final FDA approval, and will be sold under the Teva label and marketed by Teva USA.
In 2003, the FDA granted final …
-
- Teva launches Quinapril HCl tablets; pursuant to agreement with Ranbaxy.
-
News wire article from: Asia Africa Intelligence Wire
December 16, 2004
700+ words
-
- Teva announces approval of Moexipril HCl tablets.
-
News wire article from: Asia Africa Intelligence Wire
May 8, 2003
700+ words
-
- Teva announces tentative approval of Cetirizine Hcl tablets.
-
News wire article from: Asia Africa Intelligence Wire
September 22, 2004
700+ words
-
- FDA approves Teva's glipizide-metformin HCL tablets.
-
News wire article from: Asia Africa Intelligence Wire
October 31, 2005
700+ words
-
- Teva announces approval of Glyburide/Metformin Hcl tablets.
-
News wire article from: Asia Africa Intelligence Wire
January 28, 2005
700+ words
